Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy
Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sun, Yuntong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| Übergeordnetes Werk: |
Enthalten in: Tissue Engineering and Regenerative Medicine - Springer Netherlands, 2012, 20(2023), 2 vom: 13. Jan., Seite 157-175 |
|---|---|
| Übergeordnetes Werk: |
volume:20 ; year:2023 ; number:2 ; day:13 ; month:01 ; pages:157-175 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13770-022-00503-y |
|---|
| Katalog-ID: |
SPR049938371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049938371 | ||
| 003 | DE-627 | ||
| 005 | 20230405064704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230405s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13770-022-00503-y |2 doi | |
| 035 | |a (DE-627)SPR049938371 | ||
| 035 | |a (SPR)s13770-022-00503-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Yuntong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. | ||
| 650 | 4 | |a Extracellular vesicles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Engineering |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Targeted delivery |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sun, Fengtian |4 aut | |
| 700 | 1 | |a Xu, Wenrong |4 aut | |
| 700 | 1 | |a Qian, Hui |0 (orcid)0000-0002-0098-3196 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tissue Engineering and Regenerative Medicine |d Springer Netherlands, 2012 |g 20(2023), 2 vom: 13. Jan., Seite 157-175 |w (DE-627)SPR032345240 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:2 |g day:13 |g month:01 |g pages:157-175 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13770-022-00503-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_61 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_130 | ||
| 912 | |a GBV_ILN_285 | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 2 |b 13 |c 01 |h 157-175 | ||
| author_variant |
y s ys f s fs w x wx h q hq |
|---|---|
| matchkey_str |
sunyuntongsunfengtianxuwenrongqianhui:2023----:nierdxrcluavsceaaagtdeieylto |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1007/s13770-022-00503-y doi (DE-627)SPR049938371 (SPR)s13770-022-00503-y-e DE-627 ger DE-627 rakwb eng Sun, Yuntong verfasserin aut Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 Sun, Fengtian aut Xu, Wenrong aut Qian, Hui (orcid)0000-0002-0098-3196 aut Enthalten in Tissue Engineering and Regenerative Medicine Springer Netherlands, 2012 20(2023), 2 vom: 13. Jan., Seite 157-175 (DE-627)SPR032345240 nnns volume:20 year:2023 number:2 day:13 month:01 pages:157-175 https://dx.doi.org/10.1007/s13770-022-00503-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 AR 20 2023 2 13 01 157-175 |
| spelling |
10.1007/s13770-022-00503-y doi (DE-627)SPR049938371 (SPR)s13770-022-00503-y-e DE-627 ger DE-627 rakwb eng Sun, Yuntong verfasserin aut Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 Sun, Fengtian aut Xu, Wenrong aut Qian, Hui (orcid)0000-0002-0098-3196 aut Enthalten in Tissue Engineering and Regenerative Medicine Springer Netherlands, 2012 20(2023), 2 vom: 13. Jan., Seite 157-175 (DE-627)SPR032345240 nnns volume:20 year:2023 number:2 day:13 month:01 pages:157-175 https://dx.doi.org/10.1007/s13770-022-00503-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 AR 20 2023 2 13 01 157-175 |
| allfields_unstemmed |
10.1007/s13770-022-00503-y doi (DE-627)SPR049938371 (SPR)s13770-022-00503-y-e DE-627 ger DE-627 rakwb eng Sun, Yuntong verfasserin aut Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 Sun, Fengtian aut Xu, Wenrong aut Qian, Hui (orcid)0000-0002-0098-3196 aut Enthalten in Tissue Engineering and Regenerative Medicine Springer Netherlands, 2012 20(2023), 2 vom: 13. Jan., Seite 157-175 (DE-627)SPR032345240 nnns volume:20 year:2023 number:2 day:13 month:01 pages:157-175 https://dx.doi.org/10.1007/s13770-022-00503-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 AR 20 2023 2 13 01 157-175 |
| allfieldsGer |
10.1007/s13770-022-00503-y doi (DE-627)SPR049938371 (SPR)s13770-022-00503-y-e DE-627 ger DE-627 rakwb eng Sun, Yuntong verfasserin aut Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 Sun, Fengtian aut Xu, Wenrong aut Qian, Hui (orcid)0000-0002-0098-3196 aut Enthalten in Tissue Engineering and Regenerative Medicine Springer Netherlands, 2012 20(2023), 2 vom: 13. Jan., Seite 157-175 (DE-627)SPR032345240 nnns volume:20 year:2023 number:2 day:13 month:01 pages:157-175 https://dx.doi.org/10.1007/s13770-022-00503-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 AR 20 2023 2 13 01 157-175 |
| allfieldsSound |
10.1007/s13770-022-00503-y doi (DE-627)SPR049938371 (SPR)s13770-022-00503-y-e DE-627 ger DE-627 rakwb eng Sun, Yuntong verfasserin aut Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 Sun, Fengtian aut Xu, Wenrong aut Qian, Hui (orcid)0000-0002-0098-3196 aut Enthalten in Tissue Engineering and Regenerative Medicine Springer Netherlands, 2012 20(2023), 2 vom: 13. Jan., Seite 157-175 (DE-627)SPR032345240 nnns volume:20 year:2023 number:2 day:13 month:01 pages:157-175 https://dx.doi.org/10.1007/s13770-022-00503-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 AR 20 2023 2 13 01 157-175 |
| language |
English |
| source |
Enthalten in Tissue Engineering and Regenerative Medicine 20(2023), 2 vom: 13. Jan., Seite 157-175 volume:20 year:2023 number:2 day:13 month:01 pages:157-175 |
| sourceStr |
Enthalten in Tissue Engineering and Regenerative Medicine 20(2023), 2 vom: 13. Jan., Seite 157-175 volume:20 year:2023 number:2 day:13 month:01 pages:157-175 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Extracellular vesicles Engineering Targeted delivery |
| isfreeaccess_bool |
false |
| container_title |
Tissue Engineering and Regenerative Medicine |
| authorswithroles_txt_mv |
Sun, Yuntong @@aut@@ Sun, Fengtian @@aut@@ Xu, Wenrong @@aut@@ Qian, Hui @@aut@@ |
| publishDateDaySort_date |
2023-01-13T00:00:00Z |
| hierarchy_top_id |
SPR032345240 |
| id |
SPR049938371 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR049938371</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230405064704.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230405s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13770-022-00503-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049938371</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13770-022-00503-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Yuntong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Extracellular vesicles</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Engineering</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted delivery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Fengtian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wenrong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qian, Hui</subfield><subfield code="0">(orcid)0000-0002-0098-3196</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tissue Engineering and Regenerative Medicine</subfield><subfield code="d">Springer Netherlands, 2012</subfield><subfield code="g">20(2023), 2 vom: 13. Jan., Seite 157-175</subfield><subfield code="w">(DE-627)SPR032345240</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">day:13</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:157-175</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13770-022-00503-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_61</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="b">13</subfield><subfield code="c">01</subfield><subfield code="h">157-175</subfield></datafield></record></collection>
|
| author |
Sun, Yuntong |
| spellingShingle |
Sun, Yuntong misc Extracellular vesicles misc Engineering misc Targeted delivery Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| authorStr |
Sun, Yuntong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR032345240 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy Extracellular vesicles (dpeaa)DE-He213 Engineering (dpeaa)DE-He213 Targeted delivery (dpeaa)DE-He213 |
| topic |
misc Extracellular vesicles misc Engineering misc Targeted delivery |
| topic_unstemmed |
misc Extracellular vesicles misc Engineering misc Targeted delivery |
| topic_browse |
misc Extracellular vesicles misc Engineering misc Targeted delivery |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Tissue Engineering and Regenerative Medicine |
| hierarchy_parent_id |
SPR032345240 |
| hierarchy_top_title |
Tissue Engineering and Regenerative Medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR032345240 |
| title |
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| ctrlnum |
(DE-627)SPR049938371 (SPR)s13770-022-00503-y-e |
| title_full |
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| author_sort |
Sun, Yuntong |
| journal |
Tissue Engineering and Regenerative Medicine |
| journalStr |
Tissue Engineering and Regenerative Medicine |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
157 |
| author_browse |
Sun, Yuntong Sun, Fengtian Xu, Wenrong Qian, Hui |
| container_volume |
20 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sun, Yuntong |
| doi_str_mv |
10.1007/s13770-022-00503-y |
| normlink |
(ORCID)0000-0002-0098-3196 |
| normlink_prefix_str_mv |
(orcid)0000-0002-0098-3196 |
| title_sort |
engineered extracellular vesicles as a targeted delivery platform for precision therapy |
| title_auth |
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| abstract |
Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstractGer |
Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstract_unstemmed |
Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice. © Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_21 GBV_ILN_22 GBV_ILN_24 GBV_ILN_31 GBV_ILN_40 GBV_ILN_61 GBV_ILN_65 GBV_ILN_69 GBV_ILN_130 GBV_ILN_285 |
| container_issue |
2 |
| title_short |
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy |
| url |
https://dx.doi.org/10.1007/s13770-022-00503-y |
| remote_bool |
true |
| author2 |
Sun, Fengtian Xu, Wenrong Qian, Hui |
| author2Str |
Sun, Fengtian Xu, Wenrong Qian, Hui |
| ppnlink |
SPR032345240 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13770-022-00503-y |
| up_date |
2024-07-04T02:51:11.856Z |
| _version_ |
1803615177913925632 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR049938371</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230405064704.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230405s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13770-022-00503-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049938371</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13770-022-00503-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sun, Yuntong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Korean Tissue Engineering and Regenerative Medicine Society 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Extracellular vesicles</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Engineering</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted delivery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sun, Fengtian</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xu, Wenrong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qian, Hui</subfield><subfield code="0">(orcid)0000-0002-0098-3196</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Tissue Engineering and Regenerative Medicine</subfield><subfield code="d">Springer Netherlands, 2012</subfield><subfield code="g">20(2023), 2 vom: 13. Jan., Seite 157-175</subfield><subfield code="w">(DE-627)SPR032345240</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:2</subfield><subfield code="g">day:13</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:157-175</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13770-022-00503-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_61</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2023</subfield><subfield code="e">2</subfield><subfield code="b">13</subfield><subfield code="c">01</subfield><subfield code="h">157-175</subfield></datafield></record></collection>
|
| score |
7.3982906 |